Suppr超能文献

微小RNA-629-5p通过靶向A激酶锚定蛋白13促进前列腺癌的发展和转移。

MiR-629-5p Promotes Prostate Cancer Development and Metastasis by Targeting AKAP13.

作者信息

Liu Yangzhou, Zhao Shankun, Wang Jiamin, Zhu Zhiguo, Luo Lianmin, Xiang Qian, Zhou Mingda, Ma Yuxiang, Wang Zuomin, Zhao Zhigang

机构信息

Department of Urology & Andrology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of GuangZhou Medical University, Guangzhou, China.

Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.

出版信息

Front Oncol. 2021 Oct 15;11:754353. doi: 10.3389/fonc.2021.754353. eCollection 2021.

Abstract

Prostate cancer (PCa) has become the most frequently occurring cancer among western men according to the latest report, and patients' prognosis is often poor in the event of tumor progression, therefore, many researches are devoted to exploring the molecular mechanism of PCa metastasis. MicroRNAs (miRNA) have proved to play an important role in this process. In present study, by combining clinical samples with public databases, we found that miR-629-5p increased to varying degrees in primary localized PCa tissues and metastatic PCa tissues compared with adjacent normal tissues, and bioinformatics analysis suggested that high level of miR-629-5p was related to poor prognosis. Functionally, miR-629-5p drove PCa cell proliferation, migration and invasion , and promoted growth of PCa cells . Moreover, A-kinase Anchor Protein 13 (AKAP13) was screened as a direct target of miR-629-5p, that expression was negatively correlated with the malignant phenotype of tumor cells. In the end, through verification in clinical specimens, we found that AKAP13 could be independently used as a clinical prognostic indicator. Overall, the present study indicates that miR-629-5p plays an oncogenic role in PCa by targeting AKAP13, which provides a new idea for clinical diagnosis and treatment of complex refractory PCa.

摘要

根据最新报告,前列腺癌(PCa)已成为西方男性中最常见的癌症,并且在肿瘤进展的情况下患者的预后通常很差,因此,许多研究致力于探索PCa转移的分子机制。微小RNA(miRNA)已被证明在这一过程中发挥重要作用。在本研究中,通过将临床样本与公共数据库相结合,我们发现与相邻正常组织相比,miR-629-5p在原发性局限性PCa组织和转移性PCa组织中均有不同程度的升高,生物信息学分析表明miR-629-5p的高水平与不良预后相关。在功能上,miR-629-5p促进PCa细胞增殖、迁移和侵袭,并促进PCa细胞生长。此外,A激酶锚定蛋白13(AKAP13)被筛选为miR-629-5p的直接靶标,其表达与肿瘤细胞的恶性表型呈负相关。最后,通过临床标本验证,我们发现AKAP13可独立用作临床预后指标。总体而言,本研究表明miR-629-5p通过靶向AKAP13在PCa中发挥致癌作用,这为复杂难治性PCa的临床诊断和治疗提供了新思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4342/8554144/8de8eeccf4a5/fonc-11-754353-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验